These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.
Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.
Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.
ESMO ASIA 2024 | Dec 6, 2024 - Dec 8, 2024
Lung cancer is highly prevalent worldwide and the most common cause of cancer-related death. Non-small cell lung cancer (NSCLC) accounts for the vast majority of all lung cancer cases. Patients are typically diagnosed with NSCLC in advanced stages of disease (stage III/IV) and their overall survival and quality of life remain relatively poor.
